Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report | Otto et al. Journal of Medical Case Reports 2011 5 477 http www.jmedicalcasereports.eom content 5 1 477 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis A case report Sven Otto1 Karl Sotlar2 Michael Ehrenfeld1 and Christoph Pautke1 Abstract Introduction Osteonecrosis of the jaw is a serious side effect in patients receiving nitrogen-containing bisphosphonates intravenously due to malignant diseases. Albeit far less frequently osteonecrosis of the jaw has also been reported to occur due to the oral administration of nitrogen-containing bisphosphonates due to osteoporosis. Annual infusions of zoledronic acid have been recommended in order to improve patient compliance to optimize therapeutic effects and to minimize side effects. To date osteonecrosis of the jaw has not been linked to the annual administration of bisphosphonates. Case presentation We report the case of a 65-year-old Caucasian woman suffering from osteoporosis who developed early stage osteonecrosis of the jaw in two locations with chronic infections after two months of oral bisphosphonate treatment and three annual administrations of zoledronic acid. Our patient was treated by fluorescence-guided resection of the necrotic jaw bone areas local inflammation was treated by removal of a wisdom tooth and repeat root resections. Histopathology revealed typical hallmarks of osteonecrosis of the jaw. Conclusion Osteonecrosis of the jaw may occur as a consequence of annual administrations of zoledronic acid. It is conceivable that due to the pharmacological properties of bisphosphonates a jaw bone that encounters frequent local inflammations is more likely to develop osteonecrosis. Introduction Osteoporosis can be managed effectively with bisphosphonates. These antiresorptive drugs significantly prevent skeletal complications particularly fractures. Side effects of bisphosphonate therapy are
